Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLL3-CAR-NK cells in ES-SCLC
NCT05507593Phase 1Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2022
- Primary completion
- Mar 2023
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of DLL3-CAR-NK cells in small cell lung cancer (SCLC) (3 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Dose-Limiting Toxicity at 1 year and Maximum Tolerated Dose at 1 year. Status: unknown.
02
Drugs
DLL3-CAR-NK cells
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05507593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507593.